Sacituzumab Tirumotecan into spinal fluid for advanced lung cancer
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug, sacituzumab tirumotecan, given directly into the spinal fluid. It is for people with a specific type of lung cancer (EGFR-mutant) that has spread to the lining of the brain or spinal cord and has stopped responding to standard targeted pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your lung cancer has an EGFR mutation and has spread to the lining of the brain or spinal cord (confirmed by a spinal tap).
- You have already tried an EGFR-targeted pill and your cancer has continued to grow.
- Your neurological symptoms (like headaches, confusion, or weakness) have been stable for at least 7 days.
- Your blood counts, liver, and kidney function are within safe limits, and you have no active infections or severe allergies to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called sacituzumab tirumotecan (Sac-TMT) combined with radiation to the brain for people with EGFR-mutant lung cancer that has spread to the brain and has grown despite first-line EGFR inhibitor therapy. The goal is to see if this combination can control the brain tumors better.
This trial tests a new drug (Sacituzumab Tirumotecan) combined with a third-generation EGFR pill, with or without radiation, for people with EGFR-mutant lung cancer that has spread to the brain and has stopped responding to prior targeted therapy.
This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.
This trial tests a combination of two drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has gotten worse after one prior treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a new targeted drug (sacituzumab tirumotecan) for people with advanced thymic cancer that has gotten worse after at least one prior treatment. The goal is to see if the drug can shrink tumors and improve outcomes.
This trial tests if giving a higher dose of a third-generation EGFR-targeted pill (like osimertinib) along with chemotherapy injected into the spinal fluid can help people with advanced lung cancer that has spread to the lining of the brain and spinal cord (leptomeningeal metastases) after standard doses stopped working. The goal is to see if this combination works better than just the higher dose of the pill alone.
Hear when a new EGFR-TKI-resistant Non-small Cell Lung Cancer With Leptomeningeal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.